Beisland H O, Binkowitz B, Brekkan E, Ekman P, Kontturi M, Lehtonen T, Lundmo P, Pappas F, Round E, Shapiro D
Aker University Hospital, Oslo, Norway.
Eur Urol. 1992;22(4):271-7. doi: 10.1159/000474771.
The effects of finasteride, a potent 5 alpha-reductase inhibitor, were assessed in patients with benign prostatic hyperplasia. Patients were treated with finasteride or placebo for 24 weeks in a double-blind multicenter study followed by a 12-month open-extension period. After 24 weeks, finasteride-treated patients, when compared to placebo-treated patients, showed a significant reduction in prostate volume (22.5% median decrease) and prostate significant antigen (32.4% median decrease), a significant increase in maximum urinary flow (1.6 ml/s mean increase from baseline) and a significant improvement in their obstructive symptom scores (two-point decrease from baseline). Finasteride was well tolerated, and the improvements in prostate volume, maximum urinary flow rate and obstructive symptom scores observed in the controlled study were maintained throughout the extension study.
在良性前列腺增生患者中评估了强效5α-还原酶抑制剂非那雄胺的疗效。在一项双盲多中心研究中，患者接受非那雄胺或安慰剂治疗24周，随后进入为期12个月的开放延长期。24周后，与接受安慰剂治疗的患者相比，接受非那雄胺治疗的患者前列腺体积显著减小（中位数下降22.5%），前列腺特异性抗原显著降低（中位数下降32.4%），最大尿流率显著增加（较基线平均增加1.6 ml/s），梗阻症状评分显著改善（较基线下降两分）。非那雄胺耐受性良好，在对照研究中观察到的前列腺体积、最大尿流率和梗阻症状评分的改善在整个延长期内得以维持。
